Nanostics is a clinical-stage precision health company developing novel and minimally invasive diagnostic tests to bring clarity to healthcare decisions.

We designed a novel liquid biopsy platform technology called ClarityDX® that combines a highly sensitive extracellular vesicle (EV) detection platform with advanced machine learning (ML) algorithms to determine disease states from any fluid in the body.

There’s a lot riding on
your prostate test…


ClarityDX Prostate is a blood-based diagnostic test that provides a risk score based on clinical and biological biomarkers to help patients and their healthcare providers make an informed decision after an elevated PSA test result.

The ClarityDX® Platform is designed to measure the patient’s disease state.



Detecting biomarkers for disease in biofluid samples
shows that the patients’ cells are expressing organ-specific and disease-associated proteins.

Biomarker diagnostic tests are essential for diseases and disorders where there are:
  • No diagnostic tests developed.
  • Diagnostic tests that are highly sensitive but not disease-specific.
  • Genetic screening tests that can identify gene mutation(s) associated with disease but cannot determine if the patient has or will develop the disease.

Our bodies use tiny messengers called extracellular vesicles to communicate throughout the body. At Nanostics our novel platform technology deciphers these messages to better diagnose disease. We’re validating a new test that accurately diagnoses clinically significant prostate cancer from a few drops of blood.

Dr. John Lewis
Dr. John LewisCEO of Nanostics

ClarityDX Prostate is an innovative blood test that significantly advances prostate cancer screening with 3X the accuracy of the current PSA test.

It provides critical support to men with elevated PSA levels or abnormal DRE, and their primary care providers, in making more informed decisions about whether a prostate biopsy is required.

Our success is possible thanks to the support of our many Canadian and international collaborators, funders, and partners.